Nyxoah NYXH recently received FDA approval for its Genio system, an innovative therapy for moderate to severe Obstructive Sleep Apnea (OSA). Featuring a leadless, battery-free design powered by an ...

“AI can be used as a gym – a place for training, challenge, and growth – or as a diet pill, a way to bypass effort in the ...

The FDA has approved the Genio® system for treating patients with moderate to severe obstructive sleep apnea (OSA) with an ...

Nyxoah SA (NASDAQ:NYXH) saw its stock rise 9.4% after the FDA granted approval for its Genio system designed to treat ...

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

Genio is a different approach to hypoglossal nerve stimulation (HGNS) for the treatment of OSA. Genio’s unique design ...

Preliminary, Unaudited Second Quarter 2025 Financial Results and Business Updates Announced on August 8, 2025, that the U.S.

Nyxoah announced today that it received FDA approval for its Genio neuromodulation device for treating sleep apnea.

The Food and Drug Administration (FDA) has approved the Genio ® system for the treatment of patients with moderate to severe obstructive sleep apnea (OSA) with an apnea-hypopnea index (AHI) of ...